FPS
ALXN

Fieldpoint Private Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Fieldpoint Private Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-105
Closed -$16K – 1672
2021
Q1 		$16K Hold
105
– – ﹤0.01% 865
2020
Q4 		$16K Buy
+105
New +$13.5K ﹤0.01% 766
2020
Q1 		– Sell
-1,096
Closed -$119K – 618
2019
Q4 		$119K Sell
1,096
-198
-15% -$21.2K 0.03% 321
2019
Q3 		$127K Sell
1,294
-70
-5% -$7.89K 0.05% 255
2019
Q2 		$179K Hold
1,364
– – 0.06% 244
2019
Q1 		$184K Buy
1,364
+88
+7% +$10.9K 0.08% 201
2018
Q4 		$124K Sell
1,276
-1,180
-48% -$139K 0.06% 224
2018
Q3 		$341K Hold
2,456
– – 0.13% 160
2018
Q2 		$305K Buy
2,456
+70
+3% +$8.18K 0.12% 169
2018
Q1 		$266K Hold
2,386
– – 0.12% 147
2017
Q4 		$285K Buy
2,386
+594
+33% +$72.3K 0.15% 138
2017
Q3 		$251K Buy
1,792
+1,122
+167% +$152K 0.11% 172
2017
Q2 		$82K Buy
+670
New +$78K 0.06% 100

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Fieldpoint Private Securities's ALXN Position: Q2 2021 in Review

Fieldpoint Private Securities sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 105 shares — an estimated $16K sold.

Fieldpoint Private Securities first reported a position in ALXN in Q2 2017 and held it in 13 quarters. The position peaked at $341K in Q3 2018. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Fieldpoint Private Securities reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 105 Alexion Pharmaceuticals shares in Q2 2021, an estimated $16K.
  • Fieldpoint Private Securities first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 13 quarters.
  • Fieldpoint Private Securities's Alexion Pharmaceuticals position peaked at $341K in Q3 2018.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Fieldpoint Private Securities's 13F filing for Q2 2021, filed 12 Aug 2021.